0
May 16, 1990, Vol 263, No. 19 >
ARTICLE | May 16, 1990

Infectious Diseases FREE

R. Gordon Douglas, Jr, MD
JAMA. 1990;263(19):2648-2649. doi:10.1001/jama.1990.03440190104054
Text Size: A A A
Published online
Article
References

The acquired immunodeficiency syndrome (AIDS) epidemic continues to dominate the subspecialty of infectious diseases. New basic science and clinically relevant data about AIDS continue to rapidly accumulate. Zidovudine (formerly named azidothymidine [AZT]) remains the only available agent for treatment of AIDS, but its effect is limited in duration. One long-suspected explanation is the development of resistance to zidovudine by the human immunodeficiency virus (HIV). Larder and coworkers1 tested the sensitivity of HIV isolates to zidovudine in patients who had received zidovudine therapy. Most isolates obtained after 6 months or more of therapy were less sensitive than those obtained before or during the first few months of therapy. Although not proven, it is plausible that drug resistance may play a role in diminished clinical effectiveness of zidovudine after several months of therapy. If true, this finding could provide a strong argument for the use of drug combinations, either simultaneously or

REFERENCES

1 +
Larder BA, Darby G, Richman DD.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy . Science . 1989;;243:1731-1734.
2 +
Hirsch MS.  The rocky road to effective treatment of human immunodeficiency virus (HIV) infection . Ann Intern Med . 1989;;110:1-3.
3 +
Yarchoan R, Mitsuya H, Thomas RV, et al.  In vivo activity against HIV and favorable toxicity profile of 2′,3′- dideoxyinosine . Science . 1989;;245:412-415.
4 +
Desrosiers RC, Wyand MS, Kodama T, et al.  Vaccine protection against simian immunodeficiency virus infection . Proc Natl Acad Sci USA . 1989;;86:6353-6357.
5 +
Murphey-Corb M, Martin LN, Davison-Fairburn B, et al.  A formalin-inactivated whole SIV vaccine confers protection in macaques . Science . 1989;;246:1293-1297.
6 +
Kuo G, Choo Q-L, Alter HJ, et al.  An assay for circulating antibodies to a major etiologic virus of non-A, non-B hepatitis . Science . 1989;;244:362-364.
7 +
Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, Kuo G.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis . N Engl J Med . 1989;; 321:1494-1500.
8 +
Davis GL, Balart LA, Schiff ER, et al.  Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial . N Engl J Med . 1989;;321:1501-1506.
9 +
Di Bisceglie AM, Martin P, Kassianides C, et al.  Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial . N Engl J Med . 1989;;321:1506-1510.
10 +
Dooley CP, Cohen H.  The clinical significance of Campylobacter pylori . Ann Intern Med . 1988;;108:70-79.
11 +
Thys JP, Jacobs F, Motte S.  Quinolones in the treatment of lower respiratory tract infections . Rev Infect Dis . 1989;;11( (suppl 5) ):1212S-1219S.
12 +
Rubinstein E, Adam D, Moellering R Jr, Waldvogel F, eds.  Second international symposium on new quinolones . Rev Infect Dis . 1989;;11( (suppl 5) ).
13 +
Hooper DC, Wolfson JS.  Efficacy of fluoroquinolones for genital infections . Antimicrob Agents Chemother . 1989;; 33:1662-1667.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Larder BA, Darby G, Richman DD.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy . Science . 1989;;243:1731-1734.
2 +
Hirsch MS.  The rocky road to effective treatment of human immunodeficiency virus (HIV) infection . Ann Intern Med . 1989;;110:1-3.
3 +
Yarchoan R, Mitsuya H, Thomas RV, et al.  In vivo activity against HIV and favorable toxicity profile of 2′,3′- dideoxyinosine . Science . 1989;;245:412-415.
4 +
Desrosiers RC, Wyand MS, Kodama T, et al.  Vaccine protection against simian immunodeficiency virus infection . Proc Natl Acad Sci USA . 1989;;86:6353-6357.
5 +
Murphey-Corb M, Martin LN, Davison-Fairburn B, et al.  A formalin-inactivated whole SIV vaccine confers protection in macaques . Science . 1989;;246:1293-1297.
6 +
Kuo G, Choo Q-L, Alter HJ, et al.  An assay for circulating antibodies to a major etiologic virus of non-A, non-B hepatitis . Science . 1989;;244:362-364.
7 +
Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, Kuo G.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis . N Engl J Med . 1989;; 321:1494-1500.
8 +
Davis GL, Balart LA, Schiff ER, et al.  Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial . N Engl J Med . 1989;;321:1501-1506.
9 +
Di Bisceglie AM, Martin P, Kassianides C, et al.  Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial . N Engl J Med . 1989;;321:1506-1510.
10 +
Dooley CP, Cohen H.  The clinical significance of Campylobacter pylori . Ann Intern Med . 1988;;108:70-79.
11 +
Thys JP, Jacobs F, Motte S.  Quinolones in the treatment of lower respiratory tract infections . Rev Infect Dis . 1989;;11( (suppl 5) ):1212S-1219S.
12 +
Rubinstein E, Adam D, Moellering R Jr, Waldvogel F, eds.  Second international symposium on new quinolones . Rev Infect Dis . 1989;;11( (suppl 5) ).
13 +
Hooper DC, Wolfson JS.  Efficacy of fluoroquinolones for genital infections . Antimicrob Agents Chemother . 1989;; 33:1662-1667.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems